Overview

Efficacy Study of Digoxin & Ivabradine to Treat Heart Failure

Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
It is established that at a serum concentration 0.5-0.9 ng/ml digoxin is effective in patients with heart failure, especially in the presence of atrial fibrillation (AF). It is the claimed that ivabradine by lowering heart rate reduces symptoms and improves clinical outcomes in patients with heart failure. The effect of ivabradine and digoxin in heart failure was compared. Patients 22 patients with ischemic heart failure, AF, and diastolic dysfunction with preserved left ventricular systolic function were treated with digoxin and ivabradine for 3 months, according to a randomization cross-over design. Collected data Medical history, physical examination, laboratory (including proBNP and serum digoxin concentrations), ECG, 6-minute walk test, and echocardiographic data (LVEF, LAVi, e/e1 ratio).
Phase:
Phase 4
Details
Lead Sponsor:
Cocco, Giuseppe, M.D.
Collaborator:
Cardiology Office, Rheinfelden, Switzerland
Treatments:
Digoxin